First human test of new eye drop to control nearsightedness
NCT ID NCT05470881
Summary
This early-stage study tested the safety of a new eye drop called PRO-201, which contains a very low dose of atropine. Researchers gave the drops to 29 healthy volunteers for two weeks to check for side effects like light sensitivity and eye irritation. The goal is to develop a treatment that could help slow the progression of nearsightedness (myopia) in future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOPIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
IIMET Investigación e Innovación en Medicina Traslacional
Guadalajara, Jalisco, 44610, Mexico
Conditions
Explore the condition pages connected to this study.